Growth responses to human growth hormone in patients with intrauterine growth retardation

Foley, Thomas P.; Thompson, Robert G.; Shaw, M. R.; Baghdassarian, Alice; Nissley, S. Peter; Blizzard, Robert M.

doi:10.1016/s0022-3476(74)80002-8

Cited by 53 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exact role of GH in postnatal catch-up in SGA needs to be further clarified. Several attempts to induce catch-up growth with exogenous GH treatment in very short GH-sufficient IUGR children has been made [13, 14, 15, 16, 17, 18, 19, 20]. The contrast between poor spontaneous growth and growth acceleration in response to exogenous GH treatment further points to mechanism(s) that needs to be clarified.…”

Section: Postnatal Growth In Iugrmentioning

confidence: 99%

Multiple Hormone Resistance in Short Children Born with Intrauterine Growth Retardation?

Chatelain

Nicolino²,

Claris³

et al. 1998

Horm Res Paediatr

View full text Add to dashboard Cite

Intrauterine growth retardation (IUGR) is encountered in 2.5% (–2 SD) of newborns. Lack of postnatal catch-up growth is found in 8–20%. If GH secretion is increased early postnatally in IUGR, then some persistently short IUGR children may present with GH insufficiency. However, the mechanism of postnatal catch-up growth is heterogenous. The response to GH treatment with regard to plasma IGF-1, GH dose and growth velocity was analyzed in persistently short idiopathic IUGR children and compared to GH-deficient (GHD) and familial short stature (FSS) children of similar age and degree of short stature. IUGR children require both a greater basal and GH-induced plasma IGF-1 in order to achieve a growth velocity of similar magnitude to that of FSS and GHD children. These data suggest a different sensitivity to GH in IUGR compared to FSS or GHD children, sustaining the hypothesis that these idiopathic IUGR children may be partially IGF-1 resistant. The recent report of partial insulin resistance in IUGR subjects raises the possibility of an IGF-1 receptor- or post-receptor-mediated defect.

show abstract

Section: Postnatal Growth In Iugrmentioning

confidence: 99%

Multiple Hormone Resistance in Short Children Born with Intrauterine Growth Retardation?

Chatelain

Nicolino²,

Claris³

et al. 1998

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…In the pioneering attempts, GH administration has been tried in low frequency [20, 21]or low substitution doses [22, 23], and the results were not encouraging. Higher dose GH treatment has now been found to result in a pronounced acceleration of statural growth [24, 25, 26].…”

Section: Effect Of Gh Administration To the Short Sga Childmentioning

confidence: 99%

Craniofacial Growth and Dental Maturation in Short Children Born Small for Gestational Age: Effect of Growth Hormone Treatment

et al. 1998

View full text Add to dashboard Cite

Short children born small for gestational age (SGA) may be candidates for treatment with growth hormone (GH). We examined craniofacial growth and dental maturation in a cohort of short SGA children. The general growth failure of these children is reflected to a differential extent within the craniofacial complex. As a group, these children have a small retrognathic face with a relatively increased lower anterior face height; in contrast to skeletal maturation, dental age is not delayed. GH treatment in short prepubertal SGA children leads to craniofacial catch-up growth, which is particularly pronounced in regions where interstitial cartilage is involved, the result being that the facial profile becomes less convex; dental maturation does not appear to be influenced by GH treatment. In conclusion, in short SGA children, GH treatment does not only result in an increase of body stature but also in a trend towards normalization of craniofacial growth and this without notable advancement of dental maturation.

show abstract

“…Tanner’s conclusion was that growth hormone treatment was not a promising form of therapy in children with Russell-Silver syndrome. However, several authors [13, 14, 15]in North America during the 1970s (although the children were not all Russell-Silver syndrome) described that if large enough doses were given at frequent intervals, then the children responded (table 2). Using a daily growth hormone dose regimen, Stanhope et al [16]described a dramatic increase in growth rate to a growth hormone dose of 30 units/m 2 /week in a group of children who were predominantly Russell-Silver syndrome, and that this was a much greater response than an physiological replacement dose of 15 units/m 2 /week.…”

Section: Early Experience Of Growth Hormone Treatmentmentioning

confidence: 99%

Growth Hormone Treatment of Russell-Silver Syndrome

Stanhope

Albanese

Azcona³

1998

Horm Res Paediatr

View full text Add to dashboard Cite

Russell-Silver syndrome represents a special group of children with intrauterine growth retardation (IUGR) who do not experience catch-up growth and have characteristic dysmorphic features. They also have characteristics of abnormal growth hormone pulsatility, absence of catch-down growth after growth hormone therapy and inappropriate advancement of bone age during the middle childhood years. Data from children with Russell-Silver syndrome should certainly be analysed as a separate group from short children due to nondysmorphic IUGR. Initial data suggests that final height outcome will be improved by using pharmacological doses of biosynthetic human growth hormone. Indeed, the recent data supports the hypothesis of Blizzard’s group in 1974 that if growth hormone became available in sufficient quantities, then final height could be altered in IUGR children. In addition, the early recognition and treatment of spontaneous nocturnal hypoglycaemia may well improve the educational achievement of such children.

show abstract

Growth responses to human growth hormone in patients with intrauterine growth retardation

Cited by 53 publications

References 26 publications

Multiple Hormone Resistance in Short Children Born with Intrauterine Growth Retardation?

Multiple Hormone Resistance in Short Children Born with Intrauterine Growth Retardation?

Craniofacial Growth and Dental Maturation in Short Children Born Small for Gestational Age: Effect of Growth Hormone Treatment

Growth Hormone Treatment of Russell-Silver Syndrome

Contact Info

Product

Resources

About